Valeant to Sell $1.75B in Stock to Fund Bausch + Lomb Acquisition

Valeant Pharmaceuticals, based in Laval, Quebec, has announced plans to sell $1.75 billion in stock to support its acquisition of Bausch + Lomb, according to a PharmaLive report.

Advertisement
Carrie Pallardy

Valeant will pay $4.5 billion to acquire Bausch + Lomb and another $4.2 billion to cover the ophthalmic product company’s debt.

Valeant did not disclose the number of shares it plans to sell.

More Articles on Ophthalmology:
EyeCRO, Calvert Labs Partner to Perform Preclinical Studies of Ophthalmic Drugs
ForSight VISION5 Names John Maroney President, CEO
16 Statistics on Ophthalmologist Burnout

The future of payer-provider collaboration: Balancing reimbursement pressures & value-based progress

Recommended Whitepaper

Advertisement

Next Up in Ophthalmology

  • Montana physician practice acquired 

    Southlake, Texas-based Retina Consultants of America has acquired Montana Retina Consultants, according to a Feb. 5 news release.  Bozeman-based Montana…

    By: Patsy Newitt

  • Louisiana ophthalmology practice acquired 

    Vision Innovation Partners acquired Ophthalmic Associates of Alexandria (Va.), according to a Feb. 2 press release. Founded in 2010, Ophthalmic…

    By: Patsy Newitt

  • American Board of Ophthalmology names CEO

    The American Board of Ophthalmology has appointed Steven Gedde, MD, as its next CEO.  Dr. Gedde is an ophthalmologist and…

    By: Cameron Cortigiano
Advertisement

Comments are closed.